Fig 1.
Flowchart of study population and outcomes.
This is a prospective cohort study including pregnant women infected by SARS-CoV-2 during three pregnancy trimesters, referred as to PRegnancy OUtcome and child Development – Effects of SARS-CoV-2 infection Trial (PROUDEST). Information about the study population recruitment and exclusion criteria is presented in the Material and Methods section. The protocol was designed to provide primary and secondary outcomes. Details regarding the deliverables included in the primary and secondary goals are presented in the main manuscript.
Table 1.
Demographic and laboratorial features of the study population.
Table 2.
Clinical features of women infected with SARS-CoV-2 during pregnancy.
Table 3.
Demographic and clinical features of SARS-CoV-2 infection according to pregnancy trimester of SARS-CoV-2 infection diagnosis, COVID-19 severity and phase of COVID-19 at delivery.
Table 4.
COVID-19 severity according to the pregnancy trimester of SARS-CoV-2 infection diagnosis.
Table 5.
COVID-19 severity according to the phase of COVID-19 at delivery.
Table 6.
Odds ratio modeling of gestational age at delivery according to COVID-19 severity.
Table 7.
Clinical features of newborns born to mothers infected with SARS-CoV-2 during pregnancy.
Table 8.
Clinical features of newborns born to mothers with SARS-CoV-2 infection according to pregnancy trimester of SARS-CoV-2 infection diagnosis, COVID-19 severity and phase of COVID-19 at delivery.
Table 9.
Modeling counts of acute fetal distress and Apgar 1st minute score ≤7 according to the COVID-19 severity and phase of infection.